Malignant Tumors Occurring after Treatment of Aplastic Anemia
Gerard Socie, Michel Henry-Amar, Andrea Bacigalupo, Jill Hows, Andre Tichelli, Per Ljungman, Shaun R. McCann, Norbert Frickhofen, Elizabeth Van't Veer-Korthof, Eliane Gluckman, for The European Bone Marrow TransplantationSevere Aplastic Anemia Working Party
Background and Methods Recent studies have shown that long-termsurvivors of acquired aplastic anemia may be at high risk formalignant diseases. We assessed the risk of cancer after aplasticanemia was treated with immunosuppression or bone marrow transplantationand sought to identify risk factors according to treatment.The study population consisted of 860 patients treated by immunosuppressionand 748 patients who had received bone marrow transplants forthe treatment of severe aplastic anemia. The risk of cancerwas analyzed overall and according to treatment relative tothe risk in the general population. In calculating relativerisk, we excluded patients with myelodysplastic syndromes oracute leukemias arising less than 6 months after treatment,and solid cancers arising less than 12 months after treatment,because of a possible association with aplastic anemia itselfrather than with the treatment received.
Results Forty-two malignant conditions were reported in the860 patients who received immunosuppressive therapy: 19 casesof myelodysplastic syndrome, 15 cases of acute leukemia, 1 caseof non-Hodgkin's lymphoma, and 7 solid tumors. Nine were reportedin the 748 patients who received bone marrow transplants: twocases of acute leukemia and seven solid tumors. After the exclusionslisted above, the overall relative risk of cancer was 5.50 (P<0.001)as compared with that in the general European population; therisk was 5.15 (P<0.001) after immunosuppressive therapy and6.67 (P<0.001) after transplantation. The 10-year cumulativeincidence rate of cancer was 18.8 percent after immunosuppressivetherapy and 3.1 percent after transplantation. The risk factorsfor myelodysplastic syndrome or acute leukemia after immunosuppressivetherapy included the addition of androgens to the immunosuppressivetreatment (relative risk = 0.28), older age (relative risk =1.03), treatment in 1982 or later, as compared with 1981 orearlier (relative risk = 3.01), splenectomy (relative risk =3.65), and treatment with multiple courses of immunosuppression(relative risk = 2.26). Risk factors for solid tumors afterbone marrow transplantation were age (relative risk = 1.11 peryear) and the use of radiation as a conditioning regimen beforetransplantation (relative risk = 9.56); such tumors occurredonly in male patients.
Conclusions Survivors of aplastic anemia are at high risk forsubsequent malignant conditions. Myelodysplastic syndrome andacute leukemia tend to follow immunosuppressive therapy, whereasthe incidence of solid tumors is similar after immunosuppressionand after bone marrow transplantation.
Source Information
From the Hopital Saint Louis, Paris (G.S., E.G.); Institut Gustave Roussy, Villejuif, France (M.H.-A.); Ospedale S. Martino, Genoa, Italy (A.B.); Southmead Hospital, Bristol, United Kingdom (J.H.); Kantonsspital, Basel, Switzerland (A.T.); Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (P.L.); St. James Hospital, Dublin, Ireland (S.R.M.); Medizinische Klinik und Poliklinik, Universitat Ulm, Germany (N.F.); and Academisch Ziekenhuis, Leiden, the Netherlands (E.V.V.-K.). Members of the European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party are listed in the Appendix.
Address reprint requests to Dr. Socie at the Service de Greffe de Moelle et Unite de Recherche sur la Biologie des Cellules Souches (Laboratoire LEI-CEA/DSV), Hopital Saint Louis, 1 Ave. Claude Vellefaux, 75475 Paris CEDEX 10, France.
Kosaka, Y., Yagasaki, H., Sano, K., Kobayashi, R., Ayukawa, H., Kaneko, T., Yabe, H., Tsuchida, M., Mugishima, H., Ohara, A., Morimoto, A., Otsuka, Y., Ohga, S., Bessho, F., Nakahata, T., Tsukimoto, I., Kojima, S., on behalf of the Japan Childhood Aplastic Anemia S,
(2008). Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood
111: 1054-1059
[Abstract][Full Text]
Bhatia, S., Francisco, L., Carter, A., Sun, C.-L., Baker, K. S., Gurney, J. G., McGlave, P. B., Nademanee, A., O'Donnell, M., Ramsay, N. K. C., Robison, L. L., Snyder, D., Stein, A., Forman, S. J., Weisdorf, D. J.
(2007). Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood
110: 3784-3792
[Abstract][Full Text]
Teramura, M., Kimura, A., Iwase, S., Yonemura, Y., Nakao, S., Urabe, A., Omine, M., Mizoguchi, H.
(2007). Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood
110: 1756-1761
[Abstract][Full Text]
Socie, G., Mary, J.-Y., Schrezenmeier, H., Marsh, J., Bacigalupo, A., Locasciulli, A., Fuehrer, M., Bekassy, A., Tichelli, A., Passweg, J.
(2007). Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood
109: 2794-2796
[Abstract][Full Text]
Locasciulli, A., Oneto, R., Bacigalupo, A., Socie, G., Korthof, E., Bekassy, A., Schrezenmeier, H., Passweg, J., Fuhrer, M., on the behalf of the Severe Aplastic Anemia Workin,
(2007). Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. haematol
92: 11-18
[Abstract][Full Text]
Bacigalupo, A.
(2007). Aplastic Anemia: Pathogenesis and Treatment. ASH Education Book
2007: 23-28
[Abstract][Full Text]
Bagby, G. C., Meyers, G.
(2007). Bone Marrow Failure as a Risk Factor for Clonal Evolution: Prospects for Leukemia Prevention. ASH Education Book
2007: 40-46
[Abstract][Full Text]
Deeg, H. J., O'Donnell, M., Tolar, J., Agarwal, R., Harris, R. E., Feig, S. A., Territo, M. C., Collins, R. H., McSweeney, P. A., Copelan, E. A., Khan, S. P., Woolfrey, A., Storer, B.
(2006). Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood
108: 1485-1491
[Abstract][Full Text]
Enjeti, A K, Seldon, M, Braye, S
(2005). Bilateral breast lumps in a patient after sex mismatched allogeneic transplantation for aplastic anaemia. J. Clin. Pathol.
58: 670-671
[Full Text]
Bhatia, S., Robison, L. L., Francisco, L., Carter, A., Liu, Y., Grant, M., Baker, K. S., Fung, H., Gurney, J. G., McGlave, P. B., Nademanee, A., Ramsay, N. K. C., Stein, A., Weisdorf, D. J., Forman, S. J.
(2005). Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood
105: 4215-4222
[Abstract][Full Text]
Curtis, R. E., Metayer, C., Rizzo, J. D., Socie, G., Sobocinski, K. A., Flowers, M. E. D., Travis, W. D., Travis, L. B., Horowitz, M. M., Deeg, H. J.
(2005). Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood
105: 3802-3811
[Abstract][Full Text]
Rosenberg, P. S., Socie, G., Alter, B. P., Gluckman, E.
(2005). Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood
105: 67-73
[Abstract][Full Text]
Ades, L., Mary, J.-Y., Robin, M., Ferry, C., Porcher, R., Esperou, H., Ribaud, P., Devergie, A., Traineau, R., Gluckman, E., Socie, G.
(2004). Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood
103: 2490-2497
[Abstract][Full Text]
Locatelli, F., Labopin, M., Ortega, J., Meloni, G., Dini, G., Messina, C., Yaniv, I., Fagioli, F., Castel, V., Shaw, P. J., Ferrant, A., Pession, A., Socie, G., Frassoni, F.
(2003). Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood
101: 1611-1619
[Abstract][Full Text]
Spivak, J. L.
(2002). Polycythemia vera: myths, mechanisms, and management. Blood
100: 4272-4290
[Full Text]
Maciejewski, J. P., Risitano, A., Sloand, E. M., Nunez, O., Young, N. S.
(2002). Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood
99: 3129-3135
[Abstract][Full Text]
Young, N. S.
(2002). Acquired Aplastic Anemia. ANN INTERN MED
136: 534-546
[Abstract][Full Text]
D'Andrea, A. D., Dahl, N., Guinan, E. C., Shimamura, A.
(2002). Marrow Failure. ASH Education Book
2002: 58-72
[Abstract][Full Text]
Greenberg, P. L., Young, N. S., Gattermann, N.
(2002). Myelodysplastic Syndromes. ASH Education Book
2002: 136-161
[Abstract][Full Text]
Brodsky, R. A., Sensenbrenner, L. L., Smith, B. D., Dorr, D., Seaman, P. J., Lee, S. M., Karp, J. E., Brodsky, I., Jones, R. J.
(2001). Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia. ANN INTERN MED
135: 477-483
[Abstract][Full Text]
Kojima, S., Hibi, S., Kosaka, Y., Yamamoto, M., Tsuchida, M., Mugishima, H., Sugita, K., Yabe, H., Ohara, A., Tsukimoto, I.
(2000). Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood
96: 2049-2054
[Abstract][Full Text]
Mortazavi, Y., Tooze, J. A., Gordon-Smith, E. C., Rutherford, T. R.
(2000). N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/ paroxysmal nocturnal hemoglobinuria during evolution to clonal disease. Blood
95: 646-650
[Abstract][Full Text]
Young, N. S., Abkowitz, J. L., Luzzatto, L.
(2000). New Insights into the Pathophysiology of Acquired Cytopenias. ASH Education Book
2000: 18-38
[Abstract][Full Text]
Kolb, H. J., Socie, G., Duell, T., Van Lint, M. T., Tichelli, A., Apperley, J. F., Nekolla, E., Ljungman, P., Jacobsen, N., van Weel, M., Wick, R., Weiss, M., Prentice, H. G., for the Late Effects Working Party of the European,
(1999). Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation. ANN INTERN MED
131: 738-744
[Abstract][Full Text]
Kami, M., Machida, U., Hirai, H.
(1999). Late Clonal Complications in Older Patients Receiving Immunosuppressive Therapy for Aplastic Anemia. ANN INTERN MED
131: 633-633
[Full Text]
Tichelli, A., Henry-Amar, M., Gerard Socie,
(1999). Late Clonal Complications in Older Patients Receiving Immunosuppressive Therapy for Aplastic Anemia. ANN INTERN MED
131: 633-634
[Full Text]
Dunn, D. E., Tanawattanacharoen, P., Boccuni, P., Nagakura, S., Green, S. W., Kirby, M. R., Kumar, M. S. A., Rosenfeld, S., Young, N. S.
(1999). Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure Syndromes. ANN INTERN MED
131: 401-408
[Abstract][Full Text]
Wulffraat, N. M., Kuis, W.
(1999). Autologous stem cell transplantation: a possible treatment for refractory juvenile chronic arthritis?. Rheumatology (Oxford)
38: 764-766
[Abstract][Full Text]
Young, N. S.
(1999). Acquired Aplastic Anemia. JAMA
282: 271-278
[Full Text]
Marsh, J., Schrezenmeier, H., Marin, P., Ilhan, O., Ljungman, P., McCann, S., Socie, G., Tichelli, A., Passweg, J., Hows, J., Raghavachar, A., Locasciulli, A., Bacigalupo, A.
(1999). Prospective Randomized Multicenter Study Comparing Cyclosporin Alone Versus the Combination of Antithymocyte Globulin and Cyclosporin for Treatment of Patients With Nonsevere Aplastic Anemia: A Report From the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood
93: 2191-2195
[Abstract][Full Text]
Porcu, P., Neiman, R. S., Orazi;, A., Barosi, G., Guarnone, R.
(1999). Splenectomy in Agnogenic Myeloid Metaplasia. Blood
93: 2132-2134
[Full Text]
Brodsky, R. A., Mukhina, G. L., Nelson, K. L., Lawrence, T. S., Jones, R. J., Buckley, J. T.
(1999). Resistance of Paroxysmal Nocturnal Hemoglobinuria Cells to the Glycosylphosphatidylinositol-Binding Toxin Aerolysin. Blood
93: 1749-1756
[Abstract][Full Text]
Tichelli, A., Socie, G., Henry-Amar, M., Marsh, J., Passweg, J., Schrezenmeier, H., McCann, S., Hows, J., Ljungman, P., Marin, P., Raghavachar, A., Locasciulli, A., Gratwohl, A., Bacigalupo, A., for the European Group for Blood and Marrow Transp,
(1999). Effectiveness of Immunosuppressive Therapy in Older Patients with Aplastic Anemia. ANN INTERN MED
130: 193-201
[Abstract][Full Text]
Pitcher, L A, Hann, I M, Evans, J P M, Veys, P, Chessells, J M, Webb, D K H
(1999). Improved prognosis for acquired aplastic anaemia. Arch. Dis. Child.
80: 158-162
[Abstract][Full Text]
Ball, S. E., Gibson, F. M., Rizzo, S., Tooze, J. A., Marsh, J. C.W., Gordon-Smith, E. C.
(1998). Progressive Telomere Shortening in Aplastic Anemia. Blood
91: 3582-3592
[Abstract][Full Text]
Barosi, G., Ambrosetti, A., Centra, A., Falcone, A., Finelli, C., Foa, P., Grossi, A., Guarnone, R., Rupoli, S., Luciano, L., Petti, M. C., Pogliani, E., Russo, D., Ruggeri, M., Quaglini, S., Italian Cooperative Study Group on Myelofibrosis W, t.
(1998). Splenectomy and Risk of Blast Transformation in Myelofibrosis With Myeloid Metaplasia. Blood
91: 3630-3636
[Abstract][Full Text]
Takeshima, M., Mochizuki, Y., Yoshida, T., Takamatsu, H., Okumura, H.
(1998). Disappearance of Cytogenetic Abnormalities Induced by Cyclosporine Therapy in a Case of Aplastic Anemia. Blood
91: 1094-1095
[Full Text]
Ohara, A., Kojima, S., Hamajima, N., Tsuchida, M., Imashuku, S., Ohta, S., Sasaki, H., Okamura, J., Sugita, K., Kigasawa, H., Kiriyama, Y., Akatsuka, J., Tsukimoto, I.
(1997). Myelodysplastic Syndrome and Acute Myelogenous Leukemia as a Late Clonal Complication in Children With Acquired Aplastic Anemia. Blood
90: 1009-1013
[Abstract][Full Text]
Passweg, J. R., Socie, G., Hinterberger, W., Bacigalupo, A., Biggs, J. C., Camitta, B. M., Champlin, R. E., Gale, R. P., Gluckman, E., Gordon-Smith, E. C., Hows, J. M., Klein, J. P., Nugent, M. L., Pasquini, R., Rowlings, P. A., Speck, B., Tichelli, A., Zhang, M.-J., Horowitz, M. M., Bortin, M. M.
(1997). Bone Marrow Transplantation for Severe Aplastic Anemia: Has Outcome Improved?. Blood
90: 858-864
[Abstract][Full Text]
Young, N. S., Maciejewski, J.
(1997). The Pathophysiology of Acquired Aplastic Anemia. NEJM
336: 1365-1372
[Full Text]
Najean, Y., Rain, J.-D.
(1997). Treatment of Polycythemia Vera: Use of 32P Alone or in Combination With Maintenance Therapy Using Hydroxyurea in 461 Patients Greater Than 65 Years of Age. Blood
89: 2319-2327
[Abstract][Full Text]
Curtis, R. E., Rowlings, P. A., Deeg, H. J., Shriner, D. A., Socie, G., Travis, L. B., Horowitz, M. M., Witherspoon, R. P., Hoover, R. N., Sobocinski, K. A., Fraumeni, J. F., Boice, J. D., Schoch, H. G., Sale, G. E., Storb, R., Travis, W. D., Kolb, H.-J., Gale, R. P., Passweg, J. R.
(1997). Solid Cancers after Bone Marrow Transplantation. NEJM
336: 897-904
[Abstract][Full Text]
Maciejewski, J. P., Sloand, E. M., Sato, T., Anderson, S., Young, N. S.
(1997). Impaired Hematopoiesis in Paroxysmal Nocturnal Hemoglobinuria/Aplastic Anemia Is Not Associated With a Selective Proliferative Defect in the Glycosylphosphatidylinositol-Anchored Protein-Deficient Clone. Blood
89: 1173-1181
[Abstract][Full Text]
Speck, B., Nissen, C., Tichelli, A., Gratwohl, A.
(1996). Treatment of Aplastic Anemia. The Oncologist
1: 367-370
[Abstract][Full Text]